See more : McMillan Shakespeare Limited (MMS.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Korro Bio, Inc. (KRRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Korro Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Inovalis Real Estate Investment Trust (IVREF) Income Statement Analysis – Financial Results
- Global Sweeteners Holdings Limited (3889.HK) Income Statement Analysis – Financial Results
- Reliance Home Finance Limited (RELHOME.BO) Income Statement Analysis – Financial Results
- Fusion Micro Finance Limited (FUSION.BO) Income Statement Analysis – Financial Results
- Ambac Financial Group, Inc. (AMBC-WT) Income Statement Analysis – Financial Results
Korro Bio, Inc. (KRRO)
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 3.63M | 2.51M | 3.84M | 1.58M | 16.81M | 654.00K | 531.00K |
| Gross Profit | -3.63M | -2.51M | 10.23M | 35.40M | 12.13M | -654.00K | -531.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 72.70% | 95.73% | 41.92% | 0.00% | 0.00% |
| Research & Development | 57.25M | 42.20M | 23.81M | 36.66M | 18.33M | 11.58M | 11.79M |
| General & Administrative | 27.28M | 16.80M | 11.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.28M | 16.80M | 11.69M | 26.30M | 14.48M | 6.71M | 3.99M |
| Other Expenses | 0.00 | 976.00K | 13.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 84.53M | 59.00M | 35.49M | 62.95M | 32.81M | 18.29M | 15.78M |
| Cost & Expenses | 84.53M | 59.00M | 35.49M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 0.00 | 947.00K | 0.00 | 994.00K | 1.78M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 118.00K | 0.00 | 0.00 | 0.00 | 106.00K | 174.00K |
| Depreciation & Amortization | 3.63M | 2.51M | 3.84M | 1.58M | 813.00K | 654.00K | 531.00K |
| EBITDA | -80.90M | -56.49M | -33.90M | -24.90M | -17.93M | -18.41M | -19.53M |
| EBITDA Ratio | 0.00% | 0.00% | -240.97% | -70.22% | -68.62% | 0.00% | 0.00% |
| Operating Income | -84.53M | -59.00M | -35.49M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | 0.00% | -252.30% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.39M | 976.00K | 13.54M | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.15M | -58.02M | -21.96M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | -156.08% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | 27.00K | 10.00K | 2.00K | 35.00K | 0.00 | 0.00 | 1.00 |
| Net Income | -81.17M | -58.03M | -21.96M | -26.51M | -18.75M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | 0.00% | -156.09% | -71.68% | -64.76% | 0.00% | 0.00% |
| EPS | -53.09 | -227.58 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| EPS Diluted | -53.08 | -227.42 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| Weighted Avg Shares Out | 1.53M | 255.00K | 4.45M | 645.06K | 616.89K | 627.09K | 627.09K |
| Weighted Avg Shares Out (Dil) | 1.53M | 255.17K | 4.45M | 645.06K | 616.89K | 627.09K | 627.09K |
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced...
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110
Korro to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that...
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC)
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.
Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet
The consensus price target hints at a 239.5% upside potential for Korro Bio, Inc. (KRRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one...
Korro to Participate in Upcoming September Investor and Scientific Conferences
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that...
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial...
Korro to Participate in Upcoming June Investor and Scientific Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
Source: https://incomestatements.info
Category: Stock Reports